Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NBIO
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO $NBIO $NBIO
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO $NBIO $NBIO
$NBIO the time is now. $5.00 by years end. Mark it...
$NBIO the time is now. $5.00 by years end. Mark it...
$NBIO, thin and ready to move, less than 30,000,000 shares, no debt, no dilution, drugs in the pipeline.
No brainer at these leaves.
$NBIO, thin and ready to move, less than 30,000,000 shares, no debt, no dilution, drugs in the pipeline.
No brainer at these leaves.
$NBIO, thin and ready to move, less than 30,000,000 shares, no debt, no dilution, drugs in the pipeline.
No brainer at these leaves.
$NBIO, thin and ready to move, less than 30,000,000 shares, no debt, no dilution, drugs in the pipeline.
No brainer at these leaves.
$NBIO thin thin thin, ready for the next round.
$NBIO thin thin thin, ready for the next round.
$NBIO time is ticking, not much time left.
$NBIO time is ticking, not much time left.
$NBIO ding ding ding round 2 on a run to $5 about to start.
$NBIO Loading zone.
$NBIO load and hold anything you can under a buck. $5 stock and a buy out target in 12 months.
$NBIO load and hold anything you can under a buck. $5 stock and a buy out target in 12 months.
$NBIO Spectacular recovery and bounce off the lows. Chart reset. $5.00 by the end of the year.
$NBIO 28,000,000 OS, trades on air. Biotech with a robust pipeline.
$NBIO loading zone here, massive DD coming to the board.
$NBIO loading zone here, massive DD coming to the board.
Keep a close watch on $NBIO. This is the unicorn fellas.
$NBIO keep this on your watchlist.
The weeks ahead will be epic! This is just beginning.
$NBIO holding gains.
Massive DD getting posted this evening! Stand by.
$NBIO holding gains.
Massive DD getting posted this evening! Stand by.
$NBIO holding gains. Obvious attempts to short. They are going to get crushed when they try to cover. No shares fellas. $50,000 in dollar volume and this is $2.00
????????????
$NBIO loading zone
$NBIO small wall at the .72 - .74 range based on chart historicals. After that its dollar land.
$NBIO rock solid
$NBIO keeps going!!!
$5.00 by the end of the year.
Learn More Below:
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
$NBIO keeps going!!!
$5.00 by the end of the year.
Learn More Below:
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
Time to take a closer look at $NBIO...
Clean level 2's, thin float, 2 cancer drugs in clinical trials.
Learn More Below:
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
Time to take a closer look at $NBIO...
Clean level 2's, thin float, 2 cancer drugs in clinical trials.
Learn More Below:
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
$NBIO 2 game changing cancer drugs in clinical trials.
Learn More Below
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
$NBIO Biotech 2 cancer clinical trial medications, clean level 2.
Take flight!!!
$NBIO continues to melt higher! .59 new 52 week high! Something is brewing here. No shares available. It moves on air. The gift and curse I guess.
$NBIO continues to melt higher! .59 new 52 week high! Something is brewing here. No shares available. It moves on air. The gift and curse I guess.
$NBIO New 52 Weeks high .59
.59 X .635
Things are heating up here. 2 clinical trials being conducted. Breakthrough cancer medications. Clean Level 2. This one is a winner.
$5.00 min by the end of the year.